Q3 FY2026 · ended Sep 30, 2026 · Revenue $356.00M, +13.4% YoY · Filed Oct 29, 2026
Indivior Pharmaceuticals, Inc. (SUPN) files with the SEC under industry code 2834, Pharmaceutical Preparations. In Q3 of fiscal 2026, the quarter ended Sep 30, 2026, it reported revenue of $356.0 million and net income of $137.0 million. Free cash flow was $83.0 million. As of Sep 30, 2026 it held $332.0 million in cash and investments and $501.0 million in total debt.
Revenue
$356.00M
+13.4% vs year-ago quarter
Net income
$137.00M
+226.2% vs year-ago quarter
Operating cash flow
$97.00M
+348.7% vs year-ago quarter
Free cash flow
$83.00M
+240.7% vs year-ago quarter
EPS
$1.12
+239.4% vs year-ago quarter
Dividend per share
None
Shares outstanding
118.04M
-5.5% vs year-ago quarter
Net cash
$-169.00M
Q3 FY2026
Operating margin
40.6%
TTM
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- INDV (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Rockville, MD
- SEC filer status
- Large accelerated filer
- SEC CIK
- 1625297
- Former names
- Indivior Pharmaceuticals, Inc. (until Nov 2, 2026); INDIVIOR PLC (until Jan 8, 2026)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q3 FY2026 Sep 30, 2026 |
Q2 FY2026 Jun 30, 2026 |
Q1 FY2026 Mar 31, 2026 |
Q4 FY2025 Dec 31, 2025 |
Q3 FY2025 Sep 30, 2025 |
|---|---|---|---|---|---|
| Revenue | $356.0M | $343.0M | $317.0M | $358.0M | $314.0M |
| Operating income | $180.0M | $160.0M | $137.0M | $81.0M | $43.0M |
| Net income | $137.0M | $122.0M | $89.0M | $102.0M | $42.0M |
| Diluted EPS | $1.12 | $0.98 | $0.69 | $0.78 | $0.33 |
| Operating cash flow | $97.0M | $229.0M | -$9.0M | -$221.0M | -$39.0M |
| Free cash flow | $83.0M | $222.0M | -$29.0M | -$245.0M | -$59.0M |
| Total assets | $1.3B | $1.2B | $1.2B | $1.2B | $1.4B |
| Total liabilities | $1.4B | $1.4B | $1.3B | $1.3B | $1.6B |
| Stockholders' equity | -$60.0M | -$208.0M | -$144.0M | -$98.0M | -$207.0M |
| Cash and investments | $332.0M | $249.0M | $202.0M | $223.0M | $473.0M |
| Total debt | $501.0M | $509.0M | $509.0M | $351.0M | $356.0M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Other events
|
Nov 3, 2026 | Nov 3, 2026 |
| 8-K |
Current report
Material agreement, Acquisition or sale of assets, New debt, Officer or director change, Bylaw or fiscal year change, Regulation FD disclosure
|
Nov 2, 2026 | Nov 2, 2026 |
| 10-Q | Quarterly report | Oct 29, 2026 | Sep 30, 2026 |
| 8-K |
Current report
Results of operations
|
Oct 29, 2026 | Oct 29, 2026 |
| 8-K |
Current report
Shareholder vote results
|
Oct 15, 2026 | Oct 15, 2026 |
| 8-K |
Current report
Other events
|
Oct 6, 2026 | Oct 6, 2026 |
All 572 Indivior Pharmaceuticals, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.